Clinical trials: Patent
Gaucher Disease, Type 1 Gaucher Disease
A Long-Term Extension Study of AT2101 (Afegostat Tartrate) in Type 1 Gaucher Patients
This study evaluated the long-term safety and efficacy of afegostat tartrate in participants with Gaucher disease who were enrolled in a previous Phase 2 study of afegostat tartrate.
- Conditions
- Gaucher Disease, Type 1 Gaucher Disease, Gaucher Disease, Type 1
- Trial name
- NCT00813865
- Testing
- afegostat tartrate
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 8 people
- Sponsor
- Amicus Therapeutics
Depressive Disorder, Major
Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)
Multicenter, open-label, long-term extended access treatment protocol in adult patients with a primary diagnosis of MDD.
- Trial name
- NCT03668600
- Testing
- Rapastinel
- Where
- 74 sites in United States
- Volunteers
- 230 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Diffuse Large B-cell Lymphoma
Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
The purpose of this study is to determine the efficacy and safety of ofatumomab in combination with ICE chemotherapy in subjects with relapsed/refractory DLBCL following failure to combination rituximab and anthracycline based…
- Trial name
- DLBL (NCT02412267)
- Testing
- O-ICE (ofatumumab, Ifosfamide, Carboplatin, Etoposide)
- Where
- Singapore
- Volunteers
- 17 people
- Sponsor
- National Cancer Centre, Singapore
Hypertension
High Dose BAYA1040 CR: a Long Term Extension Study
This is a clinical study evaluating the safety and efficacy of long term administration of oral BAYA1040 CR 80 mg/day (40 mg twice daily) in patients with essential hypertension for whom the test drug is tolerable during the 8…
- Trial name
- NCT01355367
- Testing
- Nifedipine (Adalat, BAYA1040)
- Where
- 22 sites in Japan
- Volunteers
- 120 people
- Sponsor
- Bayer
Diabetes Mellitus, Type 2, Insulin Resistance
KurCoSmart Effects on People With Type 2 DM
The investigators aim to evaluate the effect of curcumin and virgin coconut oil extract supplementation on people with type 2 DM, including blood glucose, HbA1c levels, inflammation, body weight and insulin resistance evaluation
- Conditions
- Diabetes Mellitus, Type 2, Insulin Resistance, Inflammation, Body Weight
- Trial name
- NCT05407467
- Testing
- Curcumin and virgin coconut oil extract (KurCo Smart)
- Where
- Indonesia
- Volunteers
- 40 people
- Sponsor
- Universitas Sebelas Maret
Infant, Premature, Congenital Heart Disease
Splanchnic and Renal Tissue Oxygenation During Enteral Feedings in Neonates With Patent Ductus Arteriosus
Patent ductus arteriosus (PDA) is a common problem in the neonatal intensive care unit and can be secondary to prematurity or congenital heart disease (CHD).
- Conditions
- Infant, Premature, Congenital Heart Disease, Patent Ductus Arteriosus, Necrotizing Enterocolitis
- Trial name
- NCT03551600
- Testing
- Near-infrared spectroscopy (NIRS)
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- University of Utah
Cough
The Safety, Tolerability, PK and PD of GSK2339345 in Healthy Subjects
This is a First Time in Human (FTIH) study for the sodium channel inhibitor, GSK2339345. The study is split into two parts. Part A will assess the safety and tolerability of the new drug.
- Trial name
- FTIH (NCT01494636)
- Testing
- GSK2339345 (solution), GSK2339345 (nebulised), Lidocaine
- Where
- United Kingdom
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prostate Cancer
Docetaxel Compared With Observation in Treating Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00376792
- Testing
- docetaxel, active surveillance, adjuvant therapy
- Where
- 8 sites in Denmark, Finland and 3 more
- Volunteers
- 396 people
- Sponsor
- Scandinavian Prostate Cancer Group
Schizophrenia, Schizoaffective Disorder
A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
The purposes of this study are to characterize the pharmacokinetics of paliperidone after single- and multiple-dose administration of paliperidone ER in children and adolescent patients (>= 10 to <= 17 years of age) with…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
- Trial name
- NCT00796081
- Testing
- ER OROS paliperidone, paliperidone ER
- Volunteers
- 25 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Severe Influenza
Evaluate the Safety and Efficacy of Xiyanping in Pediatric Participants With Severe Influenza-Like Symptoms
This is a multicenter, randomized, open Label, add-on study.
- Trial name
- NCT03947411
- Testing
- Oseltamivir Phosphate, Xiyanping injection+Oseltamivir Phosphate
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Healthy
To Evaluate the PK, PD, Safety and Drug Tolerance in Healthy Volunteers
1. To evaluate the pharmacokinetic and pharmacodynamics characteristics after administration of Reference Drug or Test Drug in healthy volunteers under fasting conditions 2.
- Trial name
- NCT05433844
- Testing
- Reference Drug or Test Drug
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- JW Pharmaceutical
Dyslipidemia, Cardiovascular Disease
The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia
There will be no significant differences in the efficacy and tolerability between the test and reference formulations of atorvastatin 20 mg in these Korean adults with primary hypercholesterolemia.
- Conditions
- Dyslipidemia, Cardiovascular Disease, Hypercholesterolemia
- Trial name
- NCT01285544
- Testing
- Atorvastatin (Lipinon), Atorvastatin (Lipitor)
- Where
- South Korea
- Volunteers
- 289 people
- Sponsor
- Seoul National University Hospital
Osteoarthritis, Knee, Osteoarthritis, Hip
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
A study to show the safety of COV155 in patients with osteoarthritis of the knee or hip or moderate to severe chronic low back pain.
- Conditions
- Osteoarthritis, Knee, Osteoarthritis, Hip, Chronic Low Back Pain
- Trial name
- NCT01722864
- Testing
- COV155
- Where
- 34 sites in United States
- Volunteers
- 153 people
- Sponsor
- Mallinckrodt
Acute Hypoxemic Respiratory Failure
Benefits of Optiflow® Device for Preoxygenation Before Intubation in Acute Hypoxemic Respiratory Failure : The PREOXYFLOW Study
Oro-tracheal intubation in intensive unit care(ICU) in acute hypoxemic respiratory failure after crash induction remains a critical event.
- Trial name
- PREOXYFLOW (NCT01747109)
- Testing
- PREOXYFLOW, STANDARD FACE MASK
- Where
- 6 sites in France
- Volunteers
- 122 people
- Sponsor
- Nantes University Hospital
Rheumatoid Arthritis
An Open-label Study of CND261 in Seropositive Rheumatoid Arthritis
The purpose of the study is to evaluate the safety and efficacy of CND261 in patients with seropositive rheumatoid arthritis.
- Trial name
- NCT07052032
- Testing
- CND261
- Where
- 2 sites in Moldova, Ukraine
- Volunteers
- 47 people
- Sponsor
- Candid Therapeutics
Glabellar Frown Lines
Subject Satisfaction With AbobutulinumtoxinA Treatment
An interventional Phase 4 study to assess subject satisfaction with abobotulinumtoxinA treatment.
- Trial name
- DREAM (NCT03687736)
- Testing
- AbobotulinumtoxinA
- Where
- 6 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Melanoma, Non Small Cell Lung Cancer
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, High Grade Serous Adenocarcinoma of Ovary
- Trial name
- PRESERVE-009 (NCT05858736)
- Testing
- AI-061
- Where
- 5 sites in Australia
- Volunteers
- 18 people
- Sponsor
- OncoC4, Inc.
Hepatitis B, Chronic Hepatitis B
Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers
This is an open-label, randomized, multi-part study to evaluate the relative oral bioavailability of a tablet formulation of AL-3778 (formerly NVR 3-778) administered under fasted and fed conditions (Parts 1 and 2) and the…
- Conditions
- Hepatitis B, Chronic Hepatitis B, Viral Hepatitis B
- Trial name
- NCT03032536
- Testing
- AL-3778, Entecavir, Tenofovir disoproxil fumarate
- Where
- 2 sites in New Zealand
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
HIV Infections
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
This study compared 3 different three-drug combinations in HIV infected individuals starting their first HIV treatment regimens.
- Trial name
- PEARLS (NCT00084136)
- Testing
- Atazanavir, Didanosine (enteric-coated), Efavirenz
- Where
- 42 sites in United States, Brazil and 7 more
- Volunteers
- 1,571 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Chronic Hepatitis C
Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care
The purpose of the study is to determine whether therapy with the combination of PSI-7977 and daclatasvir (BMS-790052) with or without ribavirin is effective in treating hepatitis C virus (HCV) infection when given for 12 or 24…
- Trial name
- NCT01359644
- Testing
- PSI-7977, Daclatasvir, Ribavirin
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 350 people
- Sponsor
- Bristol-Myers Squibb